This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n8http://linked.opendata.cz/resource/drugbank/drug/DB06581/identifier/bindingdb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06581/identifier/pubchem-compound/
n7http://linked.opendata.cz/resource/drugbank/drug/DB06581/identifier/drugbank/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n6http://linked.opendata.cz/resource/drugbank/drug/DB06581/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06581/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB06581
rdf:type
n3:Drug
n3:description
Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. Bevirimat targets the protein gag-pol polyprotein. Bevirimat is derived from a betulinic acid-like compound, first isolated from <i>Syzygium claviflorum</i>, a Chinese herb. It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.
n3:generalReferences
# Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE: Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS ONE. 2007 Nov 28;2(11):e1251. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18043758 # Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO: In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol. 2006 Nov;80(22):10957-71. Epub 2006 Sep 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16956950 # Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE: Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81. Epub 2007 Jul 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17638699
n3:group
investigational
n3:halfLife
56.3 to 69.5 hours
n3:indication
Investigated for use/treatment in HIV infection.
owl:sameAs
n10:DB06581
dcterms:title
Bevirimat
adms:identifier
n6:403003 n7:DB06581 n8:50050955 n11:457928 n13:Bevirimat
n3:mechanismOfAction
Bevirimat has a novel mechanism of action, specifically inhibiting cleavage of spacer peptide 1 (SP1) from the C-terminus of capsid which results in defective core condensation. Specifically, bevirimat binds at the SP1/capsid junction, preventing cleavage by HIV protease.
n3:synonym
PA-457 YK-FH312
n3:IUPAC-Name
n4:271B4CBF-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4CC5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4CC4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4CC1-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4CC2-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4CC3-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4CBD-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4CBE-363D-11E5-9242-09173F13E4C5 n4:271B4CBB-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4CBC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4CCB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4CCC-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4CC6-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4CC7-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4CC9-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4CC8-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4CCA-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Human Immunodeficiency Virus
n3:casRegistryNumber
174022-42-5
n3:Bioavailability
n4:271B4CD1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4CD3-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4CD4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4CD0-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4CCF-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4CD2-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4CC0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4CCD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4CCE-363D-11E5-9242-09173F13E4C5